Premium
Serological tests for COVID‐19: Potential opportunities
Author(s) -
Tantuoyir Marcarious M.,
Rezaei Nima
Publication year - 2021
Publication title -
cell biology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.932
H-Index - 77
eISSN - 1095-8355
pISSN - 1065-6995
DOI - 10.1002/cbin.11516
Subject(s) - serology , covid-19 , antibody , virology , pandemic , immunology , coronavirus , betacoronavirus , antigen , medicine , immunoglobulin m , immunoglobulin g , disease , infectious disease (medical specialty) , pathology , outbreak
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a novel betacoronavirus, caused a pandemic leading to a standstill of nearly all global activities. There are some controversies on the production of specific immunoglobulin M (IgM) and IgG antibodies after the infection with SARS‐CoV‐2. This paper seeks to elaborate on the potential application of IgM and IgG antibodies and the viral antigens for the diagnosis and the course of the disease as well as the recurrence of positive nucleic acid tests after discharge.